Molecular Archaeology: Vintage Beta Lactams for Resistant Gram Negative Infectio
Molecular Archaeology: Vintage Beta Lactams for Resistant Gram Negative Infectio
批准号:
8464629
负责人:
Scott J. Hecker
金额:
$19.18万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2015-04-30
关键词:
AchievementAddressAnimalsAntibioticsArchaeologyBacteriaBacterial CountsBacterial InfectionsBiological AssayBlood flowCanis familiarisCarbapenemsChemistryClinicalData SetDevelopmentDoseDose-LimitingDrug KineticsDrug resistanceEnterobacteriaceaeEnzymesHemolysisHumanIn VitroInfectionInfusion proceduresKlebsiella pneumonia bacteriumKnowledgeLeadLiverMediatingModelingMolecularMonkeysMonobactamsNew AgentsOrganismPenicillinsPharmaceutical ChemistryPharmaceutical PreparationsPhasePlasmidsPopulationRattusRelative (related person)ResistanceRodentSafetySeriesSerineSerumStressStructure-Activity RelationshipTimeToxic effectToxicologyantimicrobial drugbeta-Lactam Resistancebeta-Lactamasebeta-Lactamscarbapenemasecytotoxicitydesigndrug candidateefflux pumpgenotoxicityin vitro activityinterestmetalloenzymenovelpathogenprototyperesistance mechanismsafety studyscaffold
中文摘要
描述(由申请人提供):我们建议对现有的β -内酰胺支架进行修饰,以解决新出现的革兰氏阴性耐药性威胁。从20世纪50年代到80年代,大量的β -内酰胺被合成,但从未被开发成抗菌药物。在当前不断增加的耐药性的压力下,随着几十年药物化学知识的积累,这些分子中的某些分子由于其对自进化以来的耐药机制不敏感而重新引起人们的兴趣。由于丝氨酸型(A、C和D类)和金属型(B类)的β -内酰胺酶的扩散,β -内酰胺类抗生素的效用受到了损害。碳青霉烯类虽然对大多数A类和C类β -内酰胺酶稳定,但对B类酶以及新出现的肺炎克雷伯菌碳青霉烯酶(KPC) A类酶敏感。相比之下,Monobactams对B类金属酶具有内在稳定性,并且我们已经合成了一种对KPC酶具有额外稳定性的原型化合物。一种不受这些酶影响的新制剂将对恢复β -内酰胺类的效用产生重大影响。我们已经评估了许多现有的、较老的β -内酰胺制剂对细菌的作用,这些细菌在β -内酰胺酶的表达和外排泵方面具有很好的特征。该数据集的结构-活性关系(SAR)使我们能够设计出一系列新的β -内酰胺分子,这些分子有望保留对当前可用药物具有抗性的生物体的有效活性。我们假设我们可以修改一个精心挑选的支架,使其对产生KPC酶的病原体具有活性,包括使其对a类和C类β -内酰胺酶有效的部分。为了实现这一点,我们在项目的探索性R21阶段提出了两个目标,为我们提供候选药物。然后,我们提出了R33阶段的三个发展目标。R21阶段的目标包括:目标1。从光谱和效价方面对所选先导化合物的体外活性进行优化。目标2。进行药代动力学(PK)研究并优化感染模型的疗效。在R33阶段进行的目标包括:目标3。进行更高级的药代动力学研究。目标4。进行体外毒理学试验和初步毒理学研究。目标5。进行为期14天的范围毒理学研究。在这个项目成功完成后,我们将准备进行ind的毒理学研究。
英文摘要
DESCRIPTION (provided by applicant): We propose that existing beta-lactam scaffolds can be modified to address the emerging threat of Gram- negative resistance. A wealth of beta-lactams were synthesized from the 1950s into the 1980s but were never developed into antimicrobial drugs. Under the current stress of increasing drug resistance, and with decades of accrued medicinal chemistry knowledge at our fingertips, certain of these molecules are of renewed interest as a result of their non-susceptibility to resistance mechanisms that have since evolved. The utility of beta-lactam antibiotics has been compromised by the spread of beta-lactamase enzymes, both of the serine type (Classes A, C and D) and the metallo type (Class B). The carbapenems, while stable to most Class A and Class C beta-lactamases, are susceptible to Class B enzymes as well as emerging Klebsiella pneumoniae carbapenemase (KPC) Class A enzymes. Monobactams, by contrast, are intrinsically stable to Class B metalloenzymes, and we have synthesized a prototype compound that is additionally stable to KPC enzymes. A new agent that is not susceptible to any of these enzymes would have a major impact on restoring the utility of the beta-lactam class. We have evaluated numerous existing, older beta-lactam agents against panels of bacteria that are well-characterized with respect to expression of beta-lactamase enzymes as well as efflux pumps. The Structure-Activity Relationships (SAR) from this data set have enabled us to design several series of new beta-lactam molecules that are expected to retain potent activity against organisms that are resistant to currently-available agents. We hypothesize that we can modify a carefully selected scaffold that is active against pathogens producing KPC enzymes to include moieties that would make it potent against Class A and Class C beta-lactamases. To accomplish this, we propose two aims in the exploratory R21 phase of the project to provide us with our drug candidate. Then we propose three development aims in the R33 phase. The aims for the R21 phase include: Aim 1. Optimize the in vitro activity of the selected lead compounds with respect to spectrum and potency. Aim 2. Conduct pharmacokinetics (PK) studies and optimize efficacy in infection models. Aims to be conducted during R33 phase include: Aim 3. Conduct higher order pharmacokinetic studies. Aim 4. Conduct in vitro toxicology battery and pilot toxicology studies. Aim 5. Conduct 14-day range-finding toxicology studies. Upon successful completion of this project, we will be ready to proceed into IND-enabling toxicology studies.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Molecular Archaeology: Vintage Beta Lactams for Resistant Gram Negative Infectio
-
批准号:8267179
-
项目类别:
-
资助金额:$21.56万
-
财政年份:2012
-
负责人:Scott J. Hecker
-
依托单位:
海外基金